Synthekine Announces Publication of Preclinical Data Demonstrating In Vivo Control of CD19 CAR-T Cells with its Orthogonal IL-2 System Portfolio News / Karina Tin December 23, 2021 Synthekine Announces Publication of Preclinical Data Demonstrating In Vivo Control of CD19 CAR-T Cells with its Orthogonal IL-2 System Read More »
Remix Therapeutics Appoints Zaven Kaprielian, Ph.D., as Chief Scientific Officer Portfolio News / Karina Tin December 15, 2021 Remix Therapeutics Appoints Zaven Kaprielian, Ph.D., as Chief Scientific Officer Read More »
Neurona Therapeutics Announces C-Suite Leadership Team Portfolio News / Karina Tin December 13, 2021 Neurona Therapeutics Announces C-Suite Leadership Team Read More »
ORIC Pharmaceuticals Presents Data Supporting the Therapeutic Potential of ORIC-533 in Multiple Myeloma at the American Society of Hematology (ASH) Annual Meeting Portfolio News / Karina Tin December 13, 2021 ORIC Pharmaceuticals Presents Data Supporting the Therapeutic Potential of ORIC-533 in Multiple Myeloma at the American Society of Hematology (ASH) Annual Meeting Read More »
Nurix Therapeutics Announces Regulatory Clearance to Initiate Phase 1 Clinical Trial of NX-5948 and Presents New Preclinical Data at the American Society of Hematology Annual Meeting Portfolio News / Karina Tin December 12, 2021 Nurix Therapeutics Announces Regulatory Clearance to Initiate Phase 1 Clinical Trial of NX-5948 and Presents New Preclinical Data at the American Society of Hematology Annual Meeting Read More »
NGM Bio Announces Clinical Trial Collaboration with Merck Related to Ongoing Phase 1/2 Trial of NGM707, an ILT2/ILT4 Dual Antagonist Antibody, in Combination with Merck’s KEYTRUDA® (pembrolizumab) Portfolio News / Karina Tin December 6, 2021 NGM Bio Announces Clinical Trial Collaboration with Merck Related to Ongoing Phase 1/2 Trial of NGM707, an ILT2/ILT4 Dual Antagonist Antibody, in Combination with Merck’s KEYTRUDA® (pembrolizumab) Read More »
Neurona Therapeutics to Present New Preclinical Data and Clinical Trial Plans for Lead Neural Cell Therapy Program, NRTX-1001, at the Annual Meeting of the American Epilepsy Society Portfolio News / Karina Tin December 3, 2021 Neurona Therapeutics to Present New Preclinical Data and Clinical Trial Plans for Lead Neural Cell Therapy Program, NRTX-1001, at the Annual Meeting of the American Epilepsy Society Read More »
